Merck & Co Inc
(LTS:0QAH)
$
131.3
0 (0%)
Market Cap: 249.37 Bil
Enterprise Value: 272.91 Bil
PE Ratio: 20.67
PB Ratio: 5.61
GF Score: 81/100 
Merck & Co Inc at Evercore ISI HealthCONx Conference Transcript
Nov 30, 2023 / 06:20PM GMT
Release Date Price:
$102.8
(+1.88%)
Umer Raffat
Evercore ISI Institutional Equities, Research Division - Senior MD & Senior Analyst of Equity Research
Listen, thank you guys for being here. Apologies, I'm a couple of minutes behind. Pleasure to have Merck management join us. This is our last fireside of this conference, at least from my end. So really looking forward to it. Peter promised it will be action-packed. And so let's jump right into it.
Questions & Answers
Umer Raffat
Evercore ISI Institutional Equities, Research Division - Senior MD & Senior Analyst of Equity Research
I think it will be a great idea, maybe let me turn it over to you, Peter and Eliav, to kick things off. Maybe frame for us what's on top in terms of priority list on your mind, and we'll jump right in.
Eliav Barr
Merck & Co., Inc. - Chief Medical Officer & Head of Global Clinical Development of Merck Research Laboratories
Sure. This has been a tremendous year for Merck, and we're looking forward to 2024. The things that are top of mind for us,
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers